Logan Coy Related postsA Multicenter, Randomized, Open-label, Phase 2 Study of BMS-986504 Monotherapy in Advanced or Metastatic NSCLC with Homozygous MTAP Deletion After Progression on Prior TherapiesSeptember 11, 2026A Phase 3, Randomized, Open-label Trial of Trastuzumab Deruxtecan with Pembrolizumab vs Platinum-based Chemotherapy with Pembrolizumab as First-line Therapy in HER2-overexpressing, PD-L1 TPS <50% Non-squamous NSCLC (DESTINY-Lung06)September 11, 2026A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)September 11, 2026 Previous postA Phase 1/2 Open-Label, Dose-Escalation Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Advanced, EGFR-Mutant, Metastatic NSCLC that Progressed after OsimertinibNext postAn Open-Label, Phase 2b Global Multicenter Cohort Trial of Zipalertinib in Locally Advanced or Metastatic NSCLC with Exon 20 Insertion and Uncommon/Single or Compound EGFR Mutations